Peggy Scherle

机构：Prelude Therapeutics Incorporated (United States) · ORCID：0000-0003-0783-6815

发表论文 388 篇 · 总被引 16999 次 · h-index 57

代表论文

• PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers (2025 · Cancer Research · 被引 20)
• PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands (2025 · Journal of Experimental & Clinical Cancer Research · 被引 13)
• Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias (2025 · Science Translational Medicine · 被引 7)
• Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs (2025 · Blood · 被引 4)
• Abstract 1646: Elucidating the molecular mechanism of action of the first in human SMARCA2 selective degrader PRT3789 (2025 · Cancer Research · 被引 2)
• Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases (2026 · Journal of Medicinal Chemistry · 被引 1)